高级检索
当前位置: 首页 > 详情页

A new personalized vaccine strategy based on inducing the pyroptosis of tumor cells in vivo by transgenic expression of a truncated GSDMD N-terminus

| 导出 | |

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Laboratory of Molecular Immunology, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China. [2]Yunnan Digestive Endoscopy Clinical Medical Center, Department of Gastroenterology, The First People's Hospital of Yunnan Province, Kunming, China. [3]Department of Acute Infectious Diseases Control and Prevention, Yunnan Provincial Center for Disease Control and Prevention, Kunming, China. [4]Institute of Medical Biology, Kunming Medical University, Kunming, China. [5]School of Life Sciences, Yunnan University, Kunming, China. [6]School of Ethnic Medicine, Yunnan Minzu University, Kunming, China.
出处:
ISSN:

关键词: GSDMD pyroptosis immunogenic cell death tumor cell vaccine antitumor immunity

摘要:
The variability and heterogeneity of tumor antigens and the tumor-driven development of immunosuppressive mechanisms leading to tumor escape from established immunological surveillance. Here, the tumor cells were genetically modified to achieve an inducible overexpression of the N-terminal domain of gasdermin D (GSDMD-NT) and effectively cause pyroptosis under a strict control. Pyroptotic tumor cells release damage-associated molecular patterns (DAMPs) and inflammatory cytokines to promote the maturation and migration of bone marrow-derived dendritic cells (BMDCs). Furthermore, local tumor delivery, and preventive or therapeutic subcutaneous immunization of the modified cells, followed by the induction of GSDMD-NT expression, significantly stimulated both the systemic and local responses of antitumor immunity, and reprogrammed the tumor microenvironment, leading to the dramatic suppression of tumor growth in mice. This study has explored the application potency of inducing the pyroptosis of tumor cells in the field of tumor immunotherapy, especially for developing a new and promising personalized tumor vaccine.Copyright © 2022 He, Zheng, Chen, Qi, Ye, Li, Yang, Yang, Liu, Hu, Zheng, Li, Hua, Yang, Chen, Huang, Sun, Yang, Long, Bai and Ma.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2022]版:
大类 | 2 区 医学
小类 | 2 区 免疫学
最新[2025]版:
大类 | 2 区 医学
小类 | 2 区 免疫学
JCR分区:
出版当年[2021]版:
Q1 IMMUNOLOGY
最新[2023]版:
Q1 IMMUNOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者:
第一作者机构: [1]Laboratory of Molecular Immunology, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China.
共同第一作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:89119 今日访问量:1 总访问量:753 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 云南省第一人民医院 技术支持:重庆聚合科技有限公司 地址:云南省昆明市西山区金碧路157号 ICP备案:滇ICP备15003244号